DIFFUSE PEDIATRIC-TYPE HIGH-GRADE GLIOMA, H3-WILDTYPE AND IDH-WILDTYPE

Clinical trials for DIFFUSE PEDIATRIC-TYPE HIGH-GRADE GLIOMA, H3-WILDTYPE AND IDH-WILDTYPE explained in plain language.

Never miss a new study

Get alerted when new DIFFUSE PEDIATRIC-TYPE HIGH-GRADE GLIOMA, H3-WILDTYPE AND IDH-WILDTYPE trials appear

Sign up with your email to follow new studies for DIFFUSE PEDIATRIC-TYPE HIGH-GRADE GLIOMA, H3-WILDTYPE AND IDH-WILDTYPE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Targeted radiation attack on deadly brain tumors begins human testing

Disease control Recruiting now

This early-stage study is testing whether a radioactive drug called Lutetium-177-PSMA-617 is safe for people with aggressive types of brain cancer called gliomas. The treatment uses a molecule that seeks out and delivers radiation directly to tumor cells that have a specific mark…

Matched conditions: DIFFUSE PEDIATRIC-TYPE HIGH-GRADE GLIOMA, H3-WILDTYPE AND IDH-WILDTYPE

Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control

Last updated Apr 01, 2026 14:41 UTC

DIFFUSE PEDIATRIC-TYPE HIGH-GRADE GLIOMA, H3-WILDTYPE AND IDH-WILDTYPE

Get alerted when new DIFFUSE PEDIATRIC-TYPE HIGH-GRADE GLIOMA, H3-WILDTYPE AND IDH-WILDTYPE trials appear

Targeted radiation attack on deadly brain tumors begins human testing